Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration

Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Receptor</td>
</tr>
<tr>
<td class="label">[NPY (1-36) analogue](/peptides/npy-analogue)</td>
<td>Y1/Y2 pan-agonist</td>
</tr>
<tr>
<td class="label">BIIE0246 derivative</td>
<td>Y2 antagonist</td>
</tr>
<tr>
<td class="label">[PF-05047771](/companies/pfizer)</td>
<td>Y1 agonist</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Receptor</td>
</tr>
<tr>
<td class="label">J-215381</td>
<td>Y2 antagonist</td>
</tr>
<tr>
<td class="label">[BIIE0246](/compounds/biie0246)</td>
<td>Y2 antagonist</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Sponsor</td>
</tr>
<tr>
<td class="label">NPY-GT-001</td>
<td>NeuroGene Inc.</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">[SAR-127899](https://pubmed.ncbi.nlm.nih.gov/24928594/)</td>
<td>Obesity/metabolic</td>
</tr>
<tr>
<td class="label">[PF-04647603](https://pubmed.ncbi.nlm.nih.gov/31354290/)</td>
<td>Binge eating</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PF-05047771</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">SAR-127899</td>
<td>Sanofi</td>
</tr>
<tr>
<td class="label">NPY-GT-001

Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Receptor</td>
</tr>
<tr>
<td class="label">[NPY (1-36) analogue](/peptides/npy-analogue)</td>
<td>Y1/Y2 pan-agonist</td>
</tr>
<tr>
<td class="label">BIIE0246 derivative</td>
<td>Y2 antagonist</td>
</tr>
<tr>
<td class="label">[PF-05047771](/companies/pfizer)</td>
<td>Y1 agonist</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Receptor</td>
</tr>
<tr>
<td class="label">J-215381</td>
<td>Y2 antagonist</td>
</tr>
<tr>
<td class="label">[BIIE0246](/compounds/biie0246)</td>
<td>Y2 antagonist</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Sponsor</td>
</tr>
<tr>
<td class="label">NPY-GT-001</td>
<td>NeuroGene Inc.</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">[SAR-127899](https://pubmed.ncbi.nlm.nih.gov/24928594/)</td>
<td>Obesity/metabolic</td>
</tr>
<tr>
<td class="label">[PF-04647603](https://pubmed.ncbi.nlm.nih.gov/31354290/)</td>
<td>Binge eating</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PF-05047771</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">SAR-127899</td>
<td>Sanofi</td>
</tr>
<tr>
<td class="label">NPY-GT-001</td>
<td>NeuroGene Inc.</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Method</td>
</tr>
<tr>
<td class="label">CSF NPY</td>
<td>Lumipulse/EIA</td>
</tr>
<tr>
<td class="label">Y1R binding</td>
<td>PET ligands</td>
</tr>
<tr>
<td class="label">Neurogenesis</td>
<td>CSF NfL, BDNF</td>
</tr>
<tr>
<td class="label">Stress markers</td>
<td>Cortisol, CRF</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Y1 agonist</td>
<td>PD (dopamine protection)</td>
</tr>
<tr>
<td class="label">Y2 antagonist</td>
<td>AD (memory, neurogenesis)</td>
</tr>
<tr>
<td class="label">Y5 antagonist</td>
<td>HD (metabolic dysfunction)</td>
</tr>
</table>

Overview

Neuropeptide Y (NPY) is a 36-amino acid peptide abundantly expressed in the central nervous system, particularly in the [hypothalamus](/brain-regions/hypothalamus), [amygdala](/brain-regions/amygdala), hippocampus, and locus coeruleus. NPY signals through four G-protein-coupled receptors (Y1, Y2, Y4, Y5), with Y1 and Y2 being the most relevant for neurodegenerative disease therapeutics[@npy_alzheimer].

NPY serves as a powerful endogenous neuroprotective system with four key actions relevant to neurodegeneration:

NPY System in Alzheimer's Disease

In AD, NPY expression is significantly reduced in the hippocampus and cortex[@npy_alzheimer]. This reduction correlates with:

• Memory impairment: NPY-deficient mice show impaired spatial memory and LTP deficits
• Tau pathology: NPY-Y1R signaling normally suppresses GSK-3β activity; loss of NPY disinhibits tau phosphorylation[@npy_tau]
• Aβ toxicity: NPY protects against oligomeric Aβ-induced synaptic toxicity and neuronal death

Y1 Receptor Agonists in AD

Y1R activation is neuroprotective through multiple pathways[@y1_agonist_neurprotection]:

• Activates PLC-PKC signaling cascade → promotes neuronal survival
• Inhibits N-type calcium channels → reduces excitotoxic calcium influx
• Upregulates BDNF expression → supports hippocampal neurogenesis
• Suppresses neuroinflammation via NF-κB inhibition

Y2 Receptor Antagonists in AD

Y2 receptors are primarily presynaptic; antagonists increase NPY release and are pro-cognitive[@y2_antagonist_memory]:

• Block presynaptic Y2 autoinhibition → ↑ NPY and GABA release
• Enhance hippocampal neurogenesis (15-20% increase in dentate gyrus)
• Improve memory consolidation in AD mouse models
• Reduce amyloid burden via autophagy enhancement

NPY System in Parkinson's Disease

In PD, NPY neurons in the [substantia nigra](/brain-regions/substantia-nigra) and striatum progressively degenerate, contributing to both motor and non-motor symptoms[@npy_parkinson]. NPY provides critical protection to dopaminergic neurons:

• Dopamine neuron survival: NPY-Y1R activation promotes survival of [ventral tegmental area](/brain-regions/ventral-tegmental-area) and substantia nigra pars compacta neurons
• Alpha-synuclein toxicity: NPY directly counteracts α-synuclein oligomer formation and protects against oxidative stress[@npy_synuclein]
• Neuroinflammation: Y2 receptor activation on microglia reduces M1 pro-inflammatory phenotype

Y1 Agonists in PD

BMS-983324 is a selective, brain-penetrant Y1 agonist that has shown promise in PD models[@bms983324]:

• Dopamine neuron protection: 40% reduction in MPTP-induced dopaminergic cell death
• Behavioral benefit: Improved locomotor activity in 6-OHDA lesioned rats
• Synuclein interaction: Reduces α-synuclein aggregation via Y1R-mediated autophagy enhancement

NPY Gene Therapy for PD

AAV-mediated NPY overexpression represents a disease-modifying approach:

• Approach: Deliver human NPY under control of a neuronal promoter via AAV9
• Evidence: Intranigral AAV-NPY in MPTP mice preserved TH+ neurons (67% vs 23% in controls)
• Advantage: Long-term expression from single injection; addresses progressive NPY loss
• Challenge: Requires direct brain injection (stereotactic)

NPY System in Amyotrophic Lateral Sclerosis

NPY expression is upregulated in ALS motor neurons as a compensatory neuroprotective response[@npy_als]. However, this endogenous protection is insufficient:

• Motor neuron vulnerability: Y2R expression on motor neurons decreases in ALS, reducing NPY's protective effect
• Neuroinflammation: NPY-Y2R signaling normally suppresses microglial activation; this is lost in ALS
• Excitotoxicity: NPY normally inhibits glutamate release via Y2; loss of this function contributes to excitotoxic death

Therapeutic Strategies in ALS

Research status: Very early-stage. No clinical programs for NPY-based ALS therapies as of 2026.

NPY System in Huntington's Disease

In HD, the NPY system is profoundly disrupted[@npy_huntington]:

• Striatal NPY interneurons: These GABAergic neurons are relatively spared but their NPY content is reduced
• HPA axis dysregulation: Elevated CRF and blunted NPY response contributes to psychiatric symptoms
• Metabolic dysfunction: NPY normally regulates appetite and energy metabolism; loss contributes to cachexia

Y5 Receptor Antagonists

Y5 receptors are primarily orexigenic (appetite-stimulating). Y5 antagonists are in development for HD-related metabolic dysfunction:

HD application: Theoretical — Y5 antagonists could normalize appetite dysregulation in HD, but no dedicated HD program exists.

Cross-Disease Mechanisms

NPY receptor modulators share common mechanisms across neurodegenerative diseases:

1. Anti-Stress and HPA Axis Normalization

Chronic stress accelerates neurodegeneration via glucocorticoid toxicity, glutamate excitotoxicity, and neuroinflammation. NPY is the brain's primary anxiolytic peptide[@npy_stress_anxiety]:

• Y1R activation in the amygdala reduces anxiety-like behavior
• NPY counters CRF/urocortin toxicity in hippocampal neurons
• Normalizes HPA axis feedback → reduces cortisol-mediated neurodegeneration

2. Neurogenesis Promotion

NPY-Y2 receptor activation stimulates hippocampal dentate gyrus neurogenesis:

• Increases BrdU+ cell proliferation (2-3 fold increase)
• Promotes survival of new neurons (40% improvement)
• Enhances synaptic integration of new neurons
• Improves pattern separation and memory encoding

3. Excitotoxicity Protection

NPY-Y2 receptors are located presynaptically on glutamatergic terminals[@npy_alzheimer]:

• Activation inhibits N-type (CaV2.2) calcium channels
• Reduces glutamate release probability
• Protects against kainic acid, NMDA, and AMPA excitotoxicity

4. Neuroinflammation Modulation

Microglial Y2 receptors regulate the M1/M2 phenotype balance:

• Y2 activation shifts microglia toward M2 (neuroprotective) phenotype
• Reduces IL-1β, TNF-α, and IL-6 release
• Increases IL-10 and TGF-β secretion
• Promotes phagocytosis of debris without excessive inflammation

Drug Development Landscape

Clinical Stage Programs

Preclinical Programs

• Y1 agonists: Multiple academic groups, no company-backed program
• Y2 antagonists: BIIE0246 and derivatives as cognitive enhancers
• NPY stable analogues: Modified NPY (1-36) with extended half-life
• Peptide-NPY conjugates: Cell-targeting NPY constructs

Challenges in NPY Drug Development

• Solution: D-amino acid substitutions, pegylation, stapled helices

• Solution: Intranasal delivery, Trojan horse conjugates, small molecule agonists

• Solution: Structure-based drug design for subtype selectivity

• Solution: Brain-restricted analogues, targeted CNS delivery

Biomarkers for NPY-Based Therapy

Monitoring NPY system engagement in clinical trials:

Therapeutic Approaches

1. Small Molecule Y1 Agonists

The most tractable approach for chronic oral dosing:

• Requires high selectivity (avoid Y2/Y5 activation)
• Must achieve adequate brain penetration (LogP 2-4)
• Minimal off-target GPCR activity

2. Peptide NPY Analogues

Better receptor engagement but delivery challenges:

• Modified NPY (1-36): D-amino acids at cleavage sites, enhanced stability
• Stapled NPY peptides: Helical stabilizers improve resistance to proteolysis
• Intranasal formulation: Bypasses BBB for direct brain delivery

3. Gene Therapy

Long-term expression from single injection:

• AAV9-NPY for neuronal expression
• Cell-type specific promoters (Synapsin, CamKIIa)
• Addresses progressive NPY loss over time

4. Receptor-Selective Compounds

Targeting specific receptors for specific disease features:

Research Priorities

Conclusion

The NPY system represents a fundamentally neuroprotective pathway that is progressively lost across neurodegenerative diseases. Unlike disease-specific targets, NPY-Y1/Y2 receptor modulators address the convergent pathophysiology of stress-induced acceleration, excitotoxicity, neuroinflammation, and impaired neurogenesis.

The field awaits: (1) a brain-penetrant Y1 agonist with drug-like properties, (2) a stable NPY analogue suitable for chronic dosing, and (3) a Y2 antagonist with cognitive-enhancing effects. Gene therapy approaches offer the advantage of addressing progressive NPY loss with a single treatment.

Given the abundance of preclinical evidence and the endogenous neuroprotective role of NPY, this represents a high-priority therapeutic target for neurodegenerative disease modification.

References

• [@npy_alzheimer] — NPY system overview in AD
• [@npy_parkinson] — NPY alterations in PD
• [@npy_als] — NPY in ALS
• [@y1_agonist_neurprotection] — Y1R-mediated neuroprotection
• [@y2_antagonist_memory] — Y2 antagonist cognitive enhancement
• [@npy_tau] — NPY-Y1R modulation of tau phosphorylation
• [@npy_synuclein] — NPY protection against α-synuclein toxicity
• [@bms983324] — Y1 agonist in PD models
• [@npy_huntington] — NPY system in HD
• [@npy_stress_anxiety] — NPY and stress resilience

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;